SARS-CoV-2 immunity in animal models
- PMID: 38238440
- PMCID: PMC10806257
- DOI: 10.1038/s41423-023-01122-w
SARS-CoV-2 immunity in animal models
Abstract
The COVID-19 pandemic, which was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a worldwide health crisis due to its transmissibility. SARS-CoV-2 infection results in severe respiratory illness and can lead to significant complications in affected individuals. These complications encompass symptoms such as coughing, respiratory distress, fever, infectious shock, acute respiratory distress syndrome (ARDS), and even multiple-organ failure. Animal models serve as crucial tools for investigating pathogenic mechanisms, immune responses, immune escape mechanisms, antiviral drug development, and vaccines against SARS-CoV-2. Currently, various animal models for SARS-CoV-2 infection, such as nonhuman primates (NHPs), ferrets, hamsters, and many different mouse models, have been developed. Each model possesses distinctive features and applications. In this review, we elucidate the immune response elicited by SARS-CoV-2 infection in patients and provide an overview of the characteristics of various animal models mainly used for SARS-CoV-2 infection, as well as the corresponding immune responses and applications of these models. A comparative analysis of transcriptomic alterations in the lungs from different animal models revealed that the K18-hACE2 and mouse-adapted virus mouse models exhibited the highest similarity with the deceased COVID-19 patients. Finally, we highlighted the current gaps in related research between animal model studies and clinical investigations, underscoring lingering scientific questions that demand further clarification.
Keywords: COVID-19; SARS-CoV-2; animal models; immune response.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures

Similar articles
-
Natural and genetically-modified animal models to investigate pulmonary and extrapulmonary manifestations of COVID-19.Int Rev Immunol. 2024;43(1):13-32. doi: 10.1080/08830185.2022.2089666. Epub 2022 Jun 25. Int Rev Immunol. 2024. PMID: 35757923 Review.
-
The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.J Virol. 2022 Jan 12;96(1):e0096421. doi: 10.1128/JVI.00964-21. Epub 2021 Oct 20. J Virol. 2022. PMID: 34668775 Free PMC article.
-
A longitudinal molecular and cellular lung atlas of lethal SARS-CoV-2 infection in K18-hACE2 transgenic mice.EBioMedicine. 2024 Jan;99:104932. doi: 10.1016/j.ebiom.2023.104932. Epub 2023 Dec 19. EBioMedicine. 2024. PMID: 38118400 Free PMC article.
-
Mouse-Adapted SARS-CoV-2 MA10 Strain Displays Differential Pulmonary Tropism and Accelerated Viral Replication, Neurodissemination, and Pulmonary Host Responses in K18-hACE2 Mice.mSphere. 2023 Feb 21;8(1):e0055822. doi: 10.1128/msphere.00558-22. Epub 2023 Feb 2. mSphere. 2023. PMID: 36728430 Free PMC article.
-
Ferrets: A powerful model of SARS-CoV-2.Zool Res. 2023 Mar 18;44(2):323-330. doi: 10.24272/j.issn.2095-8137.2022.351. Zool Res. 2023. PMID: 36799224 Free PMC article. Review.
Cited by
-
A basally active cGAS-STING pathway limits SARS-CoV-2 replication in a subset of ACE2 positive airway cell models.bioRxiv [Preprint]. 2024 Sep 6:2024.01.07.574522. doi: 10.1101/2024.01.07.574522. bioRxiv. 2024. Update in: Nat Commun. 2024 Sep 27;15(1):8394. doi: 10.1038/s41467-024-52803-7. PMID: 38260460 Free PMC article. Updated. Preprint.
-
Development and characterization of a fully humanized ACE2 mouse model.BMC Biol. 2025 Jul 1;23(1):194. doi: 10.1186/s12915-025-02293-w. BMC Biol. 2025. PMID: 40597093 Free PMC article.
-
Humanized Major Histocompatibility Complex Transgenic Mouse Model Can Play a Potent Role in SARS-CoV-2 Human Leukocyte Antigen-Restricted T Cell Epitope Screening.Vaccines (Basel). 2025 Apr 15;13(4):416. doi: 10.3390/vaccines13040416. Vaccines (Basel). 2025. PMID: 40333292 Free PMC article.
-
A basally active cGAS-STING pathway limits SARS-CoV-2 replication in a subset of ACE2 positive airway cell models.Nat Commun. 2024 Sep 27;15(1):8394. doi: 10.1038/s41467-024-52803-7. Nat Commun. 2024. PMID: 39333139 Free PMC article.
-
NK cells modulate in vivo control of SARS-CoV-2 replication and suppression of lung damage.PLoS Pathog. 2024 Aug 12;20(8):e1012439. doi: 10.1371/journal.ppat.1012439. eCollection 2024 Aug. PLoS Pathog. 2024. PMID: 39133756 Free PMC article.
References
-
- 30 November 2023. https://data.who.int/dashboards/covid19/cases?n=c.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous